These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 28468039)
21. Prognostic significance of plasma cell morphology in multiple myeloma. Carter A; Hocherman I; Linn S; Cohen Y; Tatarsky I Cancer; 1987 Sep; 60(5):1060-5. PubMed ID: 3607725 [TBL] [Abstract][Full Text] [Related]
22. Plasmablastic transformation of multiple myeloma. Lee CK; Ma ES; Shek TW; Lam CC; Au WY; Wan TS; Chan LC Hum Pathol; 2003 Jul; 34(7):710-4. PubMed ID: 12874768 [TBL] [Abstract][Full Text] [Related]
23. Morphologic and cytogenetic variables affect the flow cytometric recovery of plasma cell myeloma cells in bone marrow aspirates. Cogbill CH; Spears MD; Vantuinen P; Harrington AM; Olteanu H; Kroft SH Int J Lab Hematol; 2015 Dec; 37(6):797-808. PubMed ID: 26224420 [TBL] [Abstract][Full Text] [Related]
24. [Prognostic value of the ratio of bone marrow plasma cells in multiple myeloma]. Pasqualetti P; Colantonio D; Casale R Minerva Med; 1990 Mar; 81(3):129-33. PubMed ID: 2320280 [TBL] [Abstract][Full Text] [Related]
25. [Detection of circulating and bone marrow myeloma cells in patients with multiple myeloma and its clinical significance]. Jiang YQ; Li JY; Wu YJ; Yang H; Shen YF; Chen LJ; Xu W; Qian SX; Wu HX; Lu H; Shen RL Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Oct; 14(5):908-12. PubMed ID: 17096887 [TBL] [Abstract][Full Text] [Related]
26. Plasmablastic morphology is an independent predictor of poor survival after autologous stem-cell transplantation for multiple myeloma. Rajkumar SV; Fonseca R; Lacy MQ; Witzig TE; Therneau TM; Kyle RA; Litzow MR; Gertz MA; Greipp PR J Clin Oncol; 1999 May; 17(5):1551-7. PubMed ID: 10334543 [TBL] [Abstract][Full Text] [Related]
27. The prognostic value of diagnosing concurrent multiple myeloma in immunoglobulin light chain amyloidosis. Dinner S; Witteles W; Witteles R; Lam A; Arai S; Lafayette R; George TI; Schrier SL; Liedtke M Br J Haematol; 2013 May; 161(3):367-72. PubMed ID: 23432783 [TBL] [Abstract][Full Text] [Related]
28. Morphologic heterogeneity and plasmablastic transformation in advanced plasmacytic/plasmablastic myeloma: a study of 35 serial bone marrow biopsies in 9 patients. Paule B; Quillard J; Bennet P; Mariette X; Bisson M Nouv Rev Fr Hematol (1978); 1989; 31(3):203-8. PubMed ID: 2616267 [TBL] [Abstract][Full Text] [Related]
29. Plasma cell morphology in multiple myeloma and related disorders. Ribourtout B; Zandecki M Morphologie; 2015 Jun; 99(325):38-62. PubMed ID: 25899140 [TBL] [Abstract][Full Text] [Related]
30. CD200 expression in plasma cells of nonmyeloma immunoproliferative disorders: clinicopathologic features and comparison with plasma cell myeloma. Olteanu H; Harrington AM; Kroft SH Am J Clin Pathol; 2012 Dec; 138(6):867-76. PubMed ID: 23161721 [TBL] [Abstract][Full Text] [Related]
31. Comparing five diagnostic criteria for multiple myeloma: a retrospective study of 227 cases. Junxun L; Juan L; Xiuzhen T; Juan O; Bohuang Z; Junru L Tumori; 2014; 100(2):207-13. PubMed ID: 24852867 [TBL] [Abstract][Full Text] [Related]
32. Correlation Between Baseline 18F-FDG PET/CT Findings and CD38- and CD138-Expressing Myeloma Cells in Bone Marrow and Clinical Parameters in Patients with Multiple Myeloma. Cengiz A; Arda HÜ; Döğer F; Yavaşoğlu İ; Yürekli Y; Bolaman AZ Turk J Haematol; 2018 Aug; 35(3):175-180. PubMed ID: 29806594 [TBL] [Abstract][Full Text] [Related]
33. Prognosis value of RBBP8 expression in plasma cell myeloma. Zhang W; Song Y; He X; Liu X; Zhang Y; Yang Z; Yang P; Wang J; Hu K; Liu W; Zhang X; Yuan X; Jing H Cancer Gene Ther; 2020 Feb; 27(1-2):22-29. PubMed ID: 30622325 [TBL] [Abstract][Full Text] [Related]
34. Multiple Myeloma with Advanced Bone Disease and Low Tumor Burden - Different Clinical Presentation but Similar Outcome after Bortezomib-Based Therapy and Radiotherapy. Goranova-Marinova V; Yaneva M; Deneva T; Goranov S; Mužina Mišić D Acta Clin Croat; 2017 Jun; 56(2):262-269. PubMed ID: 29485793 [TBL] [Abstract][Full Text] [Related]
35. Malignant plasmacytes in bone marrow detected by flow cytometry as a predictor for the risk stratification system of multiple myeloma. Tian M; Liu Z; Han M; Liu H; Xiang C; Mi F; Deng L; Meng N; Fu R Cytometry B Clin Cytom; 2022 Jan; 102(1):44-49. PubMed ID: 34057806 [TBL] [Abstract][Full Text] [Related]
36. Tc-99m methoxyisobutylisonitrile bone marrow imaging for predicting the levels of myeloma cells in bone marrow in multiple myeloma: correlation with CD38/CD138 expressing myeloma cells. Ak I; Aslan V; Vardareli E; Gülbaş Z Ann Hematol; 2003 Feb; 82(2):88-92. PubMed ID: 12601486 [TBL] [Abstract][Full Text] [Related]
37. Deletion(20q) as the sole abnormality in plasma cell myeloma is not associated with plasma cells as identified by cIg FISH. White JS; Zordan A; Batzios C; Campbell LJ Cancer Genet; 2012 Dec; 205(12):644-52. PubMed ID: 23200818 [TBL] [Abstract][Full Text] [Related]
38. An approach for plasma cell myeloma diagnosis by two-color flow cytometry based on kappa/lambda ratios of CD38-gated plasma cells. Nakayama S; Yokote T; Hirata Y; Iwaki K; Akioka T; Miyoshi T; Takayama A; Nishiwaki U; Masuda Y; Ikemoto T; Tanaka H; Nishimura Y; Tsuji M; Hanafusa T Int J Immunopathol Pharmacol; 2013; 26(2):479-83. PubMed ID: 23755763 [TBL] [Abstract][Full Text] [Related]
39. Circulating Serum MicroRNA-130a as a Novel Putative Marker of Extramedullary Myeloma. Besse L; Sedlarikova L; Kryukov F; Nekvindova J; Radova L; Slaby O; Kuglik P; Almasi M; Penka M; Krejci M; Adam Z; Pour L; Sevcikova S; Hajek R PLoS One; 2015; 10(9):e0137294. PubMed ID: 26389804 [TBL] [Abstract][Full Text] [Related]
40. [Expression of Blimp-1 mRNA in Bone Marrow Mononuclear Cells in Multiple Myeloma Patients and Its Clinical Significance]. Hu WT; Liu JW; Liu HC; Wang TT Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Oct; 24(5):1443-1448. PubMed ID: 27784372 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]